Taking a Half Dose from Your Mounjaro KwikPen: What the Evidence Says

Why does the KwikPen not allow a half dose in the first place?

The Mounjaro KwikPen is an auto-injector. Press the button and it delivers the entire pre-set dose in one continuous mechanism — 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg or 15 mg depending on which pen you are using. There is no rotating barrel, no visible graduated scale, and no way to stop the delivery partway and resume it later. The dose is determined at manufacture, not by the person holding the pen.

This matters practically. Some people reason that if they press the button for a couple of seconds and then release, they will get roughly half the medication. That is not how the mechanism works. Subcutaneous injection requires the needle to be fully inserted, the button held until the delivery indicator confirms completion, and the pen held in place for a further few seconds. Interrupting any of those steps means the dose is unpredictable, some may pool under the skin, some may leak out, and you have no way of knowing what was actually absorbed. A quick check you can do in under a minute: look at the dose-indicator window before and after injecting. If it has not moved to the confirmed position, the injection was not completed correctly.

The NHS medicines page for tirzepatide and the Mounjaro SmPC on the eMC both outline the correct injection technique; neither describes a partial-dose method because none exists in the licensed device.

Is there any clinical reason a prescriber would lower a dose?

Yes, and it is not unusual. Tolerability during the early weeks (especially nausea, vomiting or diarrhoea) can be significant for some people. The licensed titration schedule exists partly to reduce that burden: starting at 2.5 mg and increasing in 4-week steps gives the body time to adjust. But even within that framework, some patients find a particular strength harder than expected.

A prescriber can decide to hold a patient at their current strength for longer before stepping up, or to move back to the previous dose temporarily if side effects are problematic. What they cannot do is prescribe a half dose by telling you to interrupt the pen, because there is no reliable way to do that. What they can do is discuss injection timing (some people tolerate weekend doses better, for example, because they can take it easy the following day) or assess whether a different licensed strength might suit you better. Tirzepatide is available in six UK strengths, and your prescriber has the clinical context to make that call properly.

If you are working out whether the current dose is right for you more broadly, our overview of how Mounjaro works as a treatment explains the titration logic in plain terms.

What should you do if your current dose feels too strong?

Contact your prescriber before your next injection. Do not skip a dose without guidance, and do not attempt to self-adjust using the pen. Skipping can affect how your body responds to treatment and may make the next injection harder to tolerate, not easier.

At nume, a real clinician reviews every repeat order before it is dispensed. There is no automated queue. If you raise a tolerability concern through our support line, it goes to a GPhC-registered prescriber who can look at your treatment record, your current strength, and what the clinical options are. That might be a note to slow your titration, or a review of whether you are on the most appropriate pen for this stage of treatment.

It is also worth reading through what the NHS England guidance on weight-management injections says about side-effect management, it reinforces that adjustments should happen within the clinical relationship, not around it. For context on how pricing and repeat prescriptions work through a private provider, the Mounjaro UK pricing page covers what changed in 2025 and what to factor in when planning ongoing treatment.

Could switching pen strength help if tolerability is the problem?

Possibly, and that is exactly the kind of question worth raising at your next clinical review. The 5 mg pen, for instance, is a step up from the starter dose that many people find manageable once the initial adjustment period is behind them. If you are struggling at 7.5 mg or above, moving back temporarily to a lower licensed strength is a real clinical option, and one your prescriber can action properly, with a new prescription for the right pen.

What does not work is treating a higher-strength pen as if it were two lower-strength pens by splitting it. The pen strengths are distinct products, dispensed separately. If you are curious about what the step below your current dose looks like in practice, the 5 mg KwikPen page and the 7.5 mg KwikPen page cover those strengths specifically. For anyone considering whether the 10 mg level is the right next move, the 10 mg KwikPen page has the relevant detail.

If any of this prompts a wider question about your treatment plan, speaking to a prescriber is the right starting point, and if you are also thinking about family planning, our page on whether Mounjaro can increase fertility is worth reading before those conversations too. Speak to our prescribers through a free consultation and get clinical input on what your dose plan should look like from here.